press releases
MicroDose Therapeutx to Present at the 30th Annual Cowen Healthcare Conference on Tuesday, March 9th
March 3, 2010
MONMOUTH JUNCTION, N.J. USA – March 3, 2010 — MicroDose Therapeutx Inc. today announced that it has been invited to give a corporate presentation at Cowen & Company, LLC’s 30th Annual Healthcare Conference being held at the Boston Marriot Copley Place, Boston, MA from Monday March 8th through Thursday, March 11th, 2010.
Read More
MicroDose Therapeutx Acquires Epix Pharmaceuticals Portfolio of Compounds for Treatment of Chronic Constipation and Irritable Bowel Syndrome with Constipation (IBS-C)
December 1, 2009
Acquisition expands MicroDose’s portfolio in its PolyCap® oral delivery platform
MONMOUTH JUNCTION, N.J. USA – December 1, 2009 — MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA). The lead compound in the portfolio, formerly known as EPX-16006, is a novel, highly selective, oral, small molecule, now called MDT-006. The compound is extremely potent, possibly allowing for once-a-day dosing, and has demonstrated efficacy and safety in preclinical studies. Because of MDT-006’s unique mechanism of action, it may also have application in non-gastrointestinal diseases. MicroDose intends to develop MDT-006 initially in an oral format using its PolyCap® delivery platform.
Read More
MicroDose Therapeutx Acquires ViroPharma Portfolio of Investigational Compounds for Treatment of Respiratory Syncytial Virus (RSV)
November 9, 2009
Acquisition expands MicroDose’s portfolio of proprietary products.
MONMOUTH JUNCTION, N.J. USA—November 9, 2009—MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637. This highly potent compound has demonstrated antiviral activity in preclinical studies in both prophylaxis and treatment, and was generally well tolerated in multiple adult volunteer Phase I studies. MicroDose plans to develop the newly acquired compound in dry powder format for inhalation via MicroDose’s novel dry powder inhaler (DPI).
Read More
MicroDose Therapeutx Announces Initiation of Phase 1 Study with Inhaled Atropine as Antidote to Combat Effects of Nerve Agent Poisoning
September 23, 2009
MONMOUTH JUNCTION, N.J. USA-September 23, 2009– MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has initiated a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI). The study is a further step in the development program for an atropine inhaler to treat nerve agent poisoning in military and civil defense applications. The program is being congressionally funded and managed through the Chemical Biological Medical Systems Joint Project Management Office to treat the symptoms, including bronchopulmonary, of mild to moderate organophosphorus poisoning after adequate amounts of injectable atropine have been administered.
Read More
Posted in: Defense.
MicroDose Therapeutx Announces Expansion of Collaboration with Merck & Co., Inc for Dry Powder Inhaler Technology
July 22, 2009
MONMOUTH JUNCTION, N.J. USA-July 22, 2009– MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that Merck & Co., Inc., through an affiliate, has exercised an option to extend its license to the MicroDose Dry Powder Inhaler (DPI) technology to an additional investigational compound. This option originates from the previously announced collaboration agreement between the two companies and triggers the payment of an undisclosed exercise fee to MicroDose.
Read More
MicroDose Technologies Becomes MicroDose Therapeutx: Name Change Reflects Expanded Vision and Opportunities
Apr 27th, 2009
FOR RELEASE – Monmouth Junction, NJ, USA—April 27, 2009— MicroDose Technologies, a leader in next generation drug delivery technologies, is now MicroDose Therapeutx (MDT). Founded in 1998 with the introduction of its revolutionary electronic dry powder inhaler among other technologies, privately held MicroDose Therapeutx focuses on the creation of products utilizing its proprietary drug delivery technologies.
Read More
MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose’s Electronic Dry Powder Inhaler
Jan 6th, 2009
MONMOUTH JUNCTION, N.J., and AUCKLAND, NEW ZEALAND, January 6, 2009 – MicroDose Technologies Inc. (MicroDose) and Nexus6 today announced that they have entered into a collaboration to investigate the application of Nexus6’s SmartinhalerLive™ technology with MicroDose’s next generation electronic dry powder inhaler (DPI).
read more
Posted in: Nexus6.
MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
Aug 5th, 2008
MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose’s dry powder inhaler (DPI) technology announced in March 2008.
read more
MicroDose Technologies Grants Global License to Merck & Co., Inc., for Use of the MicroDose Inhaler with Merck’s Proprietary Products
Mar 3rd, 2008
MONMOUTH JUNCTION, N.J., March 3 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) today announced that it has entered into a global license agreement with Merck & Co., Inc., through an affiliate, for use of MicroDose’s proprietary dry powder inhaler (DPI) with Merck compounds. This agreement follows the successful completion of an exploratory study evaluating the MicroDose DPI technology.
read more
Posted in: Merck.
MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Aug 6th, 2007
MicroDose Technologies, Inc. (PRNewsFoto/MicroDose Technologies, Inc.)
MONMOUTH JUNCTION, N.J., Aug. 6 /PRNewswire/ — MicroDose Technologies, Inc., a privately held drug delivery and specialty pharmaceuticals company, today announces top line results from a glucose clamp study of the QDose inhaled insulin product. MicroDose, through its joint venture with Vectura Group plc, QDose Limited, has developed a highly efficient, rapid acting, insulin inhaler, based upon MicroDose’s proprietary electronic inhaler technology and Vectura’s dry powder insulin formulation.
read more
Posted in: QDose.
MicroDose Technologies Announces Multi-Product Respiratory Collaboration for its Next Generation Inhaler Device
Jun 28th, 2006
MONMOUTH JUNCTION, N.J., June 28 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) announced today that it has entered into a multi-product development and licensing agreement with Novartis (NYSE: NVS) for the MicroDose proprietary dry powder inhaler (DPI). This agreement follows the successful completion of an exploratory study performed with the MicroDose DPI.
read more
Innovata and MicroDose Regain Rights to Inhaled Insulin from Bristol-Myers Squibb
Dec 7th, 2005
Nottingham, UK, December 7, 2005 – Innovata plc (LSE: IOV.L) today announced the restructuring of the agreement between QDose, its joint venture with MicroDose Technologies Inc. (MicroDose), and Bristol-Myers Squibb Company (NYSE: BMY) relating to fast acting inhaled insulin. Bristol-Myers Squibb has decided to reallocate resources dedicated to QDose to other pipeline priorities and has transferred to QDose all rights to the product.
read more
3M Drug Delivery Systems and MicroDose Technologies, Inc. Team Up to Bring Advanced Electronic Dry Powder Inhaler Technology to Market Collaboration will Provide Fully Integrated Drug Delivery Solutions for the Pharmaceutical and Biotechnology Industries
Jul 19th, 2004
St. Paul, MN — (Businesswire) — July 19, 2004 — 3M and MicroDose Technologies, Inc. a privately held drug delivery company based in Monmouth Junction, New Jersey, announced today that the two companies have entered into an exclusive co-development and joint marketing agreement.
read more
University of Pittsburgh receives Department of Defense grant to develop delivery system for nerve agent poisoning antidote
Oct 13th, 2003
Antidote Would Be Self Administered By American Forces Under the Supervision of Military Healthcare Professionals Research Will Be Conducted In Collaboration With MicroDose Technologies, Inc.
PITTSBURGH, Oct. 13, 2003 – American troops may soon have a better line of defense against chemical weapons as a result of research beginning at the University of Pittsburgh School of Medicine.
read more
Posted in: Defense.
Bristol-Myers Squibb And QDose Announce Collaboration To Develop Inhaled Insulin For The Treatment of Diabetes
Sep 10th, 2003
NEW YORK, NEW YORK (September 10, 2003) — Bristol-Myers Squibb Company (NYSE: BMY) and QDose, a joint venture between MicroDose Technologies, Inc. and Quadrant Drug Delivery, Ltd., today announced that the companies have entered into a licensing agreement for the QDose inhaled insulin product.
read more
Posted in: QDose.
Microdose Reports Success In First Clinical Trial For Inhaled Insulin Using Novel Microdose Device; Needle-Free Alternative For Diabetes Treatment
Dec 4th, 2001
Monmouth Junction, NJ, USA, 4th December 2001— MicroDose Technologies Inc. ( MicroDose ), a leading drug delivery company, announced today the successful completion of a Phase I clinical study evaluating the pulmonary delivery of human insulin, being conducted with joint venture partner, Elan Corporation, plc ( Elan ).
read more
Quadrant Healthcare PLC Joint Venture With Microdose Technologies to Exploit Pulmonary Delivery of Peptides and Proteins
Nov 30th, 1999
Nottingham, UK – 30 November 1999 – Quadrant Healthcare plc (“Quadrant” or the “Company”), the UK drug delivery company, announced today that it has agreed to form a new joint venture company with MicroDose Technologies Inc (“MicroDose”), a US based drug delivery systems company, to develop and exploit the pulmonary delivery of peptides and proteins.
read more